KLTO (Klotho Neurosciences) Debt-to-Equity: 0.00 (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KLTO Klotho Neurosciences Inc KLTO
22 GF Score
Price $0.52
! 1 Warning Sign
View Full Analysis

What is Klotho Neurosciences Debt-to-Equity?

Klotho Neurosciences KLTO 22 Debt-to-Equity is 0.00 as of Sep. 2025. GuruFocus rates KLTO with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Klotho Neurosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2025 was $0.00 Mil. Klotho Neurosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2025 was $0.00 Mil. Klotho Neurosciences's Total Stockholders Equity for the quarter that ended in Sep. 2025 was $9.93 Mil. Klotho Neurosciences's debt to equity for the quarter that ended in Sep. 2025 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Klotho Neurosciences's Debt-to-Equity or its related term are showing as below:

KLTO' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.53   Med: 1.14   Max: 2.77
Current: 0.18

During the past 4 years, the highest Debt-to-Equity Ratio of Klotho Neurosciences was 2.77. The lowest was -2.53. And the median was 1.14.

KLTO's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16 vs KLTO: 0.18

Klotho Neurosciences  (NAS:KLTO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Klotho Neurosciences Debt-to-Equity Related Terms

Klotho Neurosciences Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Klotho Neurosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Klotho Neurosciences Debt-to-Equity Chart

Klotho Neurosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
0.00 1.14 2.57 0.23

Klotho Neurosciences Quarterly Data
Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.23 2.77 0.00 0.00

KLTO vs KTTA, JUNS, ZEOX: Debt-to-Equity Comparison

For the Biotechnology subindustry, Klotho Neurosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Klotho Neurosciences Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Klotho Neurosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Klotho Neurosciences's Debt-to-Equity falls into.


KLTO
22GF Score
Klotho Neurosciences Inc KLTO
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Klotho Neurosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Klotho Neurosciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.272 + 0) / 1.185
=0.23

Klotho Neurosciences's Debt to Equity Ratio for the quarter that ended in Sep. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 9.927
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Klotho Neurosciences (KLTO) has a Debt-to-Equity of 0.00 as of Sep. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Klotho Neurosciences and its competitors.
Is Klotho Neurosciences' Debt-to-Equity too high?
Klotho Neurosciences' current Debt-to-Equity is 0.00. Overall, Klotho Neurosciences has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Klotho Neurosciences' Debt-to-Equity compare to KTTA and JUNS?
Klotho Neurosciences' Debt-to-Equity of 0.00 can be compared against companies in the Biotechnology industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Klotho Neurosciences and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Klotho Neurosciences's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klotho Neurosciences stock overvalued right now?
Klotho Neurosciences (KLTO) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Klotho Neurosciences' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Klotho Neurosciences (KLTO), the current Debt-to-Equity is 0.00 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Klotho Neurosciences Business Description

Address 13576 Walnut Street, Suite A, Omaha, NE, USA, 68144
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
22GF Score

Get the complete analysis for KLTO

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.52
Price